Cabaletta Bio Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update
March 30, 2020 07:00 ET
|
Cabaletta Bio
DSG3-CAART IND clearance received in October 2019 and Orphan Drug Designation granted by the FDA for the treatment of pemphigus vulgaris (PV) in January 2020; anticipated delay in reporting the acute...
Cabaletta Bio to Present at the Cowen and Company 40th Annual Health Care Conference
February 20, 2020 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...
FDA Grants DSG3-CAART Orphan Drug Designation for the Treatment of Pemphigus Vulgaris
January 29, 2020 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...
Cabaletta Bio to Present at the Evercore ISI 2nd Annual HealthCONx Conference
November 26, 2019 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...
Cabaletta Bio Announces Pricing of Initial Public Offering
October 25, 2019 07:36 ET
|
Cabaletta Bio
PHILADELPHIA, Oct. 25, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical stage biotechnology company focused on the discovery and development of engineered T cell therapies for...
Cabaletta Bio Announces Presentation of Preclinical Data Showing Specific CAAR T Activity against Anti-MuSK Expressing B Cells
October 07, 2019 09:00 ET
|
Cabaletta Bio
Study to be presented by the laboratory of University of Pennsylvania professor Aimee Payne, M.D., Ph.D., Cabaletta co-founder and Scientific Advisory Board co-chair, as a highlighted abstract at the...
Cabaletta Bio Receives IND Clearance from FDA to Initiate First Clinical Trial of DSG3-CAART in Patients with Mucosal Pemphigus Vulgaris
October 01, 2019 09:00 ET
|
Cabaletta Bio
First IND clearance of a product candidate derived from the CABA™ platform PHILADELPHIA, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Company), a clinical-stage biotechnology company...
Cabaletta Bio Expands Management Team with Appointment of Brian Stalter as General Counsel
September 05, 2019 10:30 ET
|
Cabaletta Bio
PHILADELPHIA, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc., a biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune...
Autoimmune Clinical Drug Development Expert, David J. Chang, M.D., M.P.H., Joins Cabaletta Bio as Chief Medical Officer
July 15, 2019 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, July 15, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc., a biotechnology company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases,...
Cabaletta Bio Appoints Distinguished Immunotherapist and Cell Therapy Expert, Catherine Bollard, M.D., to its Board of Directors
April 02, 2019 08:00 ET
|
Cabaletta Bio
RADNOR, Pa., April 02, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc., a biotechnology company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases,...